XTalks

DECEMBER 13, 2023

3) Fulgent Genetics Compound annual growth rate: 260 percent Fulgent Genetics, headquartered in California, is a technology-driven company with a strong presence in clinical diagnostics and therapeutic development. The company achieved core revenues of $67 million, reflecting a remarkable 48 perecent year-over-year growth.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Scienmag

DECEMBER 16, 2020

15, 2020 — The Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has identified a specific genetic target that could help explain the tremendous variation in how sick those infected with COVID-19 become. Comparative analysis of human and animal coronaviruses strains implicates miR1307 PHOENIX, Ariz.

Gene 40

Gene Genome Genomics Genetics 40

Scienmag

APRIL 28, 2021

Supporting families of children with developmental differences SEATTLE and GAITHERSBURG, MD. April 28) – The University of Washington’s School of Medicine Brotman Baty Institute for Precision Medicine is collaborating with Illumina, Inc. Nasdaq: ILMN) and GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc.,

Genome 56

Genome Genomics Medicine Bioinformatics 56

XTalks

MAY 20, 2022

There are different fields to explore as a clinical scientist — these include clinical bioinformatics, physiological sciences, pathology, medical physics and more. Rehabilitation Engineering. Genetic Science. Below is a brief preview from the National Health Services’ list of healthcare science fields: Vascular Science.

Scientist 105

Scientist Life Science Clinical Research Doctors 105

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

JULY 26, 2023

With 100-fold the number of genes in the human genome 1 , this microbial collection is a rich genetic signature of clinical significance that we have only recently gained the tools to explore. By Katie Gillette , Senior Project Leader, Eliza French , Analyst, and Graham Friedman , Analyst, DeciBio.

Medicine 52

Medicine Genome Genomics Bioinformatics 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. from engineered peptide and antibody libraries’. Harriman will present ‘Discovering functional modulators of the ion channel Kv1.3

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

NOVEMBER 15, 2022

The brainchild of multidisciplinary experts in computer science, physics, engineering, and biology, the field of synthetic biology has not only rapidly progressed in the last few decades but it’s also becoming more accessible and cost-effective. Synthetic libraries for antibody drug discovery .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

pharmaphorum

MARCH 28, 2022

AION Labs’ third call for applications seeks computational biologists, bioinformatics and cheminformatics scientists, AI researchers, and antibody or protein engineers at academic and industry research labs worldwide to assemble a fully funded start-up company. From there, they evaluate what kind of antibodies are produced.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98